Palvella Therapeutics (PVLA) Assets (2013 - 2026)
Palvella Therapeutics (PVLA) posted quarterly Assets of $263.8 million for Q1 2026, up 232.03% year-over-year from $79.4 million in Q1 2025, and up 342.85% quarter-over-quarter from $59.6 million in Q4 2025.
Palvella Therapeutics (PVLA) Assets (2013 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Assets for 14 consecutive years, with $263.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets rose 232.03% year-over-year to $263.8 million; the TTM figure through Mar 2026 stood at $263.8 million (up 232.03% YoY), while the FY2025 annual figure was $59.6 million, down 32.5% from the prior year.
- Assets rose to $263.8 million in Q1 2026 per PVLA's latest filing, from $59.6 million in the prior quarter.
- Across five years, Assets topped out at $263.8 million in Q1 2026 and bottomed at $7.5 million in Q4 2023.
- Historically, Assets has averaged $81.7 million across 5 years, with a median of $79.4 million in 2025.
- Annual changes were most pronounced in 2023 — Assets plunged 92.1% — and 2024, when it surged 1068.97%.
- Palvella Therapeutics' Assets stood at $95.5 million in 2022, then slumped by 92.1% to $7.5 million in 2023, then soared by 1068.97% to $88.2 million in 2024, then tumbled by 32.5% to $59.6 million in 2025, then jumped by 342.85% to $263.8 million in 2026.
- Business Quant data shows PVLA's Assets at $263.8 million in Q1 2026, $59.6 million in Q4 2025, and $66.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Palvella Therapeutics | 2.25 Bn | 1.93 Bn | - | 253.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 253.51 Mn |
| Mar 31, 2026 | 263.76 Mn |
| Dec 31, 2025 | 59.56 Mn |
| Sep 30, 2025 | 66.94 Mn |
| Jun 30, 2025 | 73.75 Mn |
| Mar 31, 2025 | 79.44 Mn |
| Dec 31, 2024 | 88.23 Mn |
| Sep 30, 2024 | 20.52 Mn |
| Jun 30, 2024 | 25.05 Mn |
| Mar 31, 2024 | 29.50 Mn |
| Dec 31, 2023 | 7.55 Mn |
| Sep 30, 2023 | 59.38 Mn |
| Jun 30, 2023 | 87.54 Mn |
| Mar 31, 2023 | 82.26 Mn |
| Dec 31, 2022 | 95.49 Mn |
| Sep 30, 2022 | 99.16 Mn |
| Jun 30, 2022 | 114.31 Mn |
| Mar 31, 2022 | 137.12 Mn |
| Dec 31, 2021 | 153.56 Mn |
| Sep 30, 2021 | 164.18 Mn |